Holen Sie sich die Stockscreener-App
1.93
0.52%
0.01
Handel nachbörslich:
1.92
-0.01
-0.52%
Schlusskurs vom Vortag:
$1.92
Offen:
$1.93
24-Stunden-Volumen:
1.69M
Relative Volume:
0.60
Marktkapitalisierung:
$311.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.7615
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
-8.96%
1M Leistung:
-81.79%
6M Leistung:
-84.99%
1J Leistung:
-87.05%
1-Tages-Spanne:
$1.90
$2.01
1-Wochen-Bereich:
$1.8648
$2.18
52-Wochen-Spanne:
$1.83
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
490 ARSENAL WAY, SUITE 200, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.93 | 311.81M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neumora Therapeutics and Other Stocks Suffer Major Losses as Market Faces Declines - HPBL
Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Neumora Stock Hits Record Low on Depression Drug Study Failure - MSN
Neumora shares slump after depression drug fails in key trial - MSN
William Blair Reiterates Outperform Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
William Blair Reiterates "Outperform" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals - MSN
Neumora Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Bank of America Issues Pessimistic Forecast for Neumora Therapeutics (NASDAQ:NMRA) Stock Price - Defense World
Traders Purchase High Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics's SWOT analysis: navacaprant setback tests resilience of CNS-focused biotech stock - Investing.com
Neumora’s Major Setback with Navacaprant Program: Industry Reacts - Zenopa
Stock Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora stock faces skepticism after failed trial, but BofA remains optimistic - Investing.com Canada
Bank of America Cuts Neumora Therapeutics (NASDAQ:NMRA) Price Target to $7.00 - MarketBeat
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
What is William Blair's Estimate for NMRA FY2029 Earnings? - MarketBeat
Stock in Biotech Neumora Plunges 80% as Depression Drug Fails - MSN
Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $23.40 - Defense World
Neumora shares look oversold after 80% drop, says Mizuho - Yahoo Finance
Neumora Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Neumora Therapeutics stock reiterated at Buy by analyst following KOASTAL-1 result - Investing.com Canada
Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops - MSN
Mizuho reiterates Outperform on Neumora Therapeutics stock post navacaprant data - Investing.com Canada
Neumora’s KOSTAL-1 Study of Navacaprant Yields Disappointing Results - Contract Pharma
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression - Yahoo Finance
Neumora fails in late-stage trial for depression therapy - MSN
Neumora shares sink following Phase III flop in MDD - MSN
Neumora tanks as KOASTAL-1 study of navacaprant misses - The Pharma Letter
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):